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“T
he Secretary of the Department of Health and Human
Services…has identified personalized health care as
one of the Department’s top priorities, and pharmacogenetics
is an important component of making health care more
personalized.”
1 This statement, from an employee of the FDA,
coincides with the change in labeling for warfarin therapy, which
stated that: “…lower initiation doses should be considered for
patients with certain genetic variations in CYP2C9 and
VKORC1…”
2 Although the statement seems relatively innocu-
ous, it raises the question of whether physicians should be
determining an individual’sg e n o t y p eb e f o r ep r o c e e d i n gw i t h
warfarin therapy. The importance of pharmacogenetics or phar-
macogenomics cannot be denied as evidenced by examples of
other drugs whose altered metabolism results in important
clinical outcomes or where genetic mutations influence a re-
sponse to a specific therapy.
3–5 But was this change in labeling
for warfarin therapy a rush to judgment on the part of the FDA to
fulfill its goal of advancing personalized medicine or a proper
response to the available data?
Warfarin is a stereo isomer of two enantiomers, the S
enantiomer having the principal biologic effect of interfering
with vitamin K metabolism (Fig. 1).
6 S-warfarin is metabolized
by the P450 cytochrome oxidase, 2C9. Two relatively common
single nucleotide polymorphisms are responsible for altering
the metabolic function of CYP2C9 leading to impaired drug
metabolism, accumulation of warfarin, and further elevation of
the INR. Warfarin’s major target is the vitamin K oxide
reductase complex 1 (VKORC1). Several polymorphisms in
combination lead to haplotypes with either enhanced or
reduced sensitivity to warfarin. In addition to genetic factors
that affect warfarin’s pharmacokinetic and pharmacodynamic
behavior, warfarin effect is also influenced by age, gender, body
surface area, dietary vitamin K content, liver function, and
multiple drug interactions. Thus, pharmacogenetic-based dos-
ing by itself is not a solution to improved therapeutic
effectiveness, but must be considered along with these other
factors. Complex dosing equations, some of which are freely
available on the web, incorporate many of these factors.
7
Warfarin may seem like the “poster child” for pharmacoge-
netic dose management. Its pharmacokinetics are well char-
acterized; the gene encoding for its major metabolic enzyme
has been identified; numerous single nucleotide polymorph-
isms (SNPs) have been described, manifesting impaired warfa-
rin metabolism.
8 Warfarin’s pharmacodynamics have also
been elucidated with the gene encoding for its enzymatic target
recently identified
9, and numerous haplotypes described
resulting in enhanced or impaired sensitivity to warfarin.
10
In the span of less than 10 years multiple retrospective
analyses have also described the frequency of genetic variants
in ethnic populations and correlated genetic variants with
altered dose requirements as well as bleeding complications.
Warfarin dosing, however, is different from all other medica-
tions (except unfractionated heparin) in that it requires intense
dose monitoring to maintain a therapeutic effect, and it has a
simple assay to determine the effect (i.e., the prothrombin time
expressed as the International Normalized Ratio or INR). One
must then address several questions: (1) Does pharmacoge-
netic-based dosing add any additional value to INR monitoring,
such as fewer adverse events, more rapid achievement of
therapeutic anticoagulation, shorter hospitalizations, or less
frequent INR monitoring; (2) if so, is the additional cost of
pharmacogenetic-based dosing worth the additional benefit;
(3) is access to pharmacogenetic testing practical at this time.
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Figure 1. The interrelationships between vitamin K, coagulation
factors, and warfarin. Prothrombin, representative of the vitamin K-
dependent coagulation factors (II, VII, IX, and X), requires reduced
vitamin K to become fully functional. Vitamin K is oxidized and then
recycled. S-warfarin’s pharmacologic effect is mediated by inter-
fering with the vitamin K oxide reductase enzyme and the
recycling of vitamin K. S-warfarin is metabolized by P450 enzyme
CYP2C9. Published online March 26, 2009
690Only recently have prospective randomized trials attempted to
assess some of these outcome parameters.
Kangelaris et al.
11, in this issue of the Journal, perform a
systematic review of randomized, controlled trials of pharma-
cogenetic-based dosing of warfarin. They quickly discover
several facts: of over 1,700 citations on the topic, there are
only 3 randomized, controlled trials; of these trials, not only
are their designs less than ideal, the trials are underpowered to
yield the important outcomes of interest, and there is such
heterogeneity between the trials that making unified conclu-
sions is difficult. Most problematic is that the intervention arm
of each trial is considerably different. One trial incorporates
CYP2C9 and VKORC1 genetic data, along with age, weight,
gender, and amiodarone use into their algorithm; another uses
six different algorithms based on CYP2C9 genetic data with
modifications based on amiodarone use; the third uses
CYP2C9 data along with age, body surface area, the presence
or absence of a heart valve, diabetes, and other factors. The
authors found no statistically significant difference in bleeding
rates or time within the therapeutic INR range, and they
concluded that there was insufficient evidence to support
pharmacogenetic-based warfarin dosing at this time. If the
outcome had been positive, what would the practicing physi-
cian take away from this analysis? What algorithm is pre-
ferred? How would one use the complicated formulas required?
Is the genetic test available on a timely basis? Is the cost of
testing worth the potential benefit?
This last question was recently addressed by Eckman
et al.
12 using data from the literature and applying it to a
hypothetical case of atrial fibrillation. They found that geno-
typing was unlikely to be cost effective for the average patient,
but may be cost effective (< $50,000 per quality adjusted life
year) for patients with a high risk of hemorrhage who are
starting therapy. In the current issue of the Journal, Eckman
et al.
13 further analyze the question of cost effectiveness by
asking the interesting question of whether treatment decisions
for patients with atrial fibrillation (AF) based on a risk/benefit
analysis can be enhanced by knowledge of CYP2C9 culprit
alleles for impaired enzyme function that are reported to be
associated with increased bleeding. In other words, they
further enhance the bleeding risk assessment side of the
equation by factoring in the presence or absence of a variant
CYP2C9 enzyme. The authors develop a Markov decision
model based on an average risk case of AF and use data from
the literature based entirely on retrospective reports of in-
creased bleeding with CYP2C9 alleles resulting in enzymes
with reduced function. The premise is that if the risk of stroke
is low (but not necessarily low enough to exclude warfarin as
the treatment of choice), and the risk of bleeding high due to
possession of a culprit allele, then treatment with aspirin
(associated with a lower risk of drug-induced bleeding) has
greater value than warfarin. However, prospective data have
yet to confirm the increased bleeding seen in retrospective
reports, nor is it clear what the increased bleeding is due to,
other than unstable or non-therapeutic INRs. It is difficult to
accept the premise that acquiring such knowledge would lead
one to use a less effective therapy, rather than using that
knowledge to guide the physician towards more intense INR
monitoring, which might abrogate the risk of bleeding.
14
Further complicating this issue is the recent study by Klein et
al.
15 showing, retrospectively, in a large international cohort of
patients that a pharmacogenetic-based dose algorithm predicted
the therapeutic dose better than a clinical algorithm only for
patients taking ≤21 mg/week or ≥49 mg/week, neither of which
would be known to a practitioner prior to dosing a patient.
What then does the clinician need to know about pharmaco-
genetic-based dosing of warfarin therapy? First, well-designed,
prospective, randomized trials of pharmacogenetic-based dos-
ing ofwarfarin therapy largeenough toyield important outcomes
havenotbeendone.Second,thefewsmallstudiesthathavebeen
completed are poorly designed, are quite heterogeneous, and
haveshown mixed results in achieving a therapeutic range faster
or increasing time in range. Third, cost effectiveness studies
using retrospective outcome data and hypothetical case scenar-
ios have not shown testing to be generally cost effective. Lastly,
pharmacogenetic-based dosing is not simple; it requires timely
acquisition of genetic assays and the use of complex dosing
formulas. This does not mean that properly designed studies
should not be done, only that it is too early to recommend such
testing. A recently funded NIH study
16 may answer some of the
these questions, but even this study is not projected to be large
enough to address whether or not pharmacogenetic-based
dosing will lead to fewer major bleeds or thrombotic episodes
compared to good INR-based dose management.
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